DiaMedica Therapeutics (DMAC) Non-Current Assets (2017 - 2026)
DiaMedica Therapeutics (DMAC) posted quarterly Non-Current Assets of $717000.0 for Q1 2026, down 49.08% year-over-year from $1.4 million in Q1 2025, and down 3.37% quarter-over-quarter from $742000.0 in Q4 2025.
DiaMedica Therapeutics (DMAC) Non-Current Assets (2017 - 2026) Analysis & Trends
DiaMedica Therapeutics' Non-Current Assets history runs 10 years deep, the most recent figure standing at $717000.0 for Q1 2026.
- In Q1 2026, Non-Current Assets fell 49.08% year-over-year to $717000.0; the TTM figure through Mar 2026 stood at $717000.0 (down 49.08% YoY), while the FY2025 annual figure was $742000.0, down 57.23% from the prior year.
- Non-Current Assets for Q1 2026 stood at $717000.0, down from $742000.0 in the prior quarter.
- The five-year high for Non-Current Assets was $20.8 million in Q2 2023, with the low at $85000.0 in Q2 2022.
- The 5-year median for Non-Current Assets is $742000.0 (2025), against an average of $2.6 million.
- The sharpest annual moves came in 2023 and 2024: Non-Current Assets surged 24392.94% in 2023, then sank 91.46% in 2024.
- DiaMedica Therapeutics' Non-Current Assets stood at $560000.0 in 2022, then declined by 13.39% to $485000.0 in 2023, then surged by 257.73% to $1.7 million in 2024, then slumped by 57.23% to $742000.0 in 2025, then retreated by 3.37% to $717000.0 in 2026.
- Business Quant data shows DMAC's Non-Current Assets at $717000.0 in Q1 2026, $742000.0 in Q4 2025, and $824000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | DiaMedica Therapeutics | 360.22 Mn | 360.22 Mn | - | 686,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 686,000.00 |
| Mar 31, 2026 | 717,000.00 |
| Dec 31, 2025 | 742,000.00 |
| Sep 30, 2025 | 824,000.00 |
| Jun 30, 2025 | 391,000.00 |
| Mar 31, 2025 | 1.41 Mn |
| Dec 31, 2024 | 1.74 Mn |
| Sep 30, 2024 | 1.76 Mn |
| Jun 30, 2024 | 1.78 Mn |
| Mar 31, 2024 | 1.78 Mn |
| Dec 31, 2023 | 485,000.00 |
| Sep 30, 2023 | 10.25 Mn |
| Jun 30, 2023 | 20.82 Mn |
| Mar 31, 2023 | 543,000.00 |
| Dec 31, 2022 | 560,000.00 |
| Sep 30, 2022 | 551,000.00 |
| Jun 30, 2022 | 85,000.00 |
| Mar 31, 2022 | 100,000.00 |
| Dec 31, 2021 | 112,000.00 |
| Sep 30, 2021 | 127,000.00 |